Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$53.20 USD

53.20
3,871,981

+2.00 (3.91%)

Updated Jul 25, 2024 03:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Arpita Dutt headshot

3 Stocks in Focus as Biotech M&A Hopes for 2018 Rise

With tax reform on the horizon, the biotech sector is expected to witness a surge in M&A deals. Here is a look at Juno (JUNO) and two other biotech stocks that could be on the acquisition radar.

    Sanofi Begins Combo Studies on Multiple Myeloma Candidate

    Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.

      Arpita Dutt headshot

      Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz

      FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.

        Novo Nordisk's Semaglutide Gets FDA Approval for Diabetes

        Novo Nordisk (NVO) announced that the FDA approved semaglutide, which is a once-weekly injection approved to improve glycaemic control in adults with type II diabetes mellitus.

          Sanofi's Toujeo Meets Key Objective in Head-to-Head Study

          Sanofi's (SNY) head-to-head study comparing Toujeo long-acting insulin to Novo Nordisk's Tresiba long-acting insulin (insulin degludec) meets its objective.

            Amgen's PCSK9 Inhibitor Gets FDA Nod for Stroke Prevention

            Amgen (AMGN) announced FDA approval of its regulatory application seeking approval to expand Repatha's label to prevent heart attacks and strokes in patients with established cardiovascular disease.

              Alnylam's RNAi Candidate Gains Breakthrough Therapy Status

              Alnylam (ALNY) announced that the FDA has granted Breakthrough Therapy Designation for RNAi therapeutic candidate, patisiran.

                Alnylam Starts Rolling NDA Submission for RNAi Candidate

                Alnylam (ALNY) has started rolling New Drug Application to the FDA for its RNAi candidate, patisiran.

                  Why is Alnylam's (ALNY) Stock Up More Than 200% this Year?

                  Alnylam (ALNY) expects to achieve the profile of three marketed products by the end of 2020 and remains focused on development of its pipeline candidates.

                    Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA

                    Alnylam's (ALNY) RNAi candidate, patisiran, has been granted accelerated assessment by the European Medicines Agency. The company expects to file new drug application by end of 2017.

                      Arpita Dutt headshot

                      Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day

                      Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.

                        Impax (IPXL) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y

                        Impax (IPXL) reported dismal third-quarter results with earnings and sales coming in lower than the year-ago period. However, the company beat estimates on both counts.

                          Arpita Dutt headshot

                          Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod

                          Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.

                            Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up

                            Regeneron reported impressive results in the third quarter driven by strong performance of Eylea.

                              Alnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates

                              Alnylam Pharmaceuticals (ALNY) incurred wider than expected loss and missed sales estimates in the third quarter of 2017.

                                Emergent (EBS) Q3 Earnings Beat Estimates, Guidance Raised

                                Emergent's (EBS) earnings and revenues beat estimates in Q3. Revenues also rise year over year on higher product sales and increase in contract manufacturing revenues.

                                  Will Regeneron Pharma (REGN) Disappoint in Q3 Earnings?

                                  Investor focus should be on Eylea's performance and uptake of Dupixent when Regeneron Pharmaceuticals (REGN) reports third-quarter results

                                    Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q3

                                    Immune Design (IMDZ) reported narrower-than-expected loss and missed sales estimates in the third-quarter 2017.

                                      Sanofi (SNY) Q3 Earnings In Line, Sales Lag, Diabetes Weak

                                      Sanofi's (SNY) Q3 results were mixed as it reported in-line earnings and missed sales expectations. Meanwhile, the outlook for the Diabetes franchise remains weak.

                                        BioMarin (BMRN) Q3 Loss Narrows, Profit Guidance Raised

                                        BioMarin (BMRN) reported a narrower-than-expected loss in the third quarter of 2017 but missed estimates for sales. The biotech also raised its previously issued adjusted net income guidance for 2017.

                                          Merck (MRK) Q3 Earnings Top, Sales Lag, Keytruda Stays Strong

                                          Merck (MRK) beat estimates for earnings but missed the same for sales in Q3. Despite the sales miss, Merck raised its adjusted earnings guidance for 2017 while increasing its sales guidance marginally.

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: Lilly Tops on All Fronts, Mixed Results from Bristol-Myers

                                            It was all about earnings this week with companies like Eli Lilly (LLY), Bristol-Myers Squibb and Novartis reporting third quarter results.

                                              Amgen (AMGN) Q3 Earnings Top, Sales Decline Y/Y, Stock Falls

                                              Though Amgen (AMGN) beat estimates on both earnings & sales and raised its earnings outlook, shares declined in after-hours trading due to the year-over-year decline in revenues.

                                                Lilly (LLY) Beats on Q3 Earnings, Explores Sale of Elanco

                                                Eli Lilly (LLY) beat estimates for both sales and earnings in Q3 and upped its 2017 outlook. Separately, the company said that it is exploring strategic alternatives for the Elanco Animal Health business.

                                                  Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi

                                                  Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi